Investor

British Patient Capital

UK government-backed investor funding high-growth fast-growing companies, based in Sheffield

Visit Website Get introducedRequest an introduction Write a Review

TrustList summary

British Patient Capital is an investment organisation that puts long-term capital behind high-growth British companies. Its own website presents it under the line of funding innovation from Sheffield.

Services

Direct investment: participation in funding rounds, such as a Series C round for a company named Perspectum.
Fund investment: commitments to venture funds, for example a biotech crossover opportunities fund alongside Mubadala.
Life sciences backing: an investment in Grey Wolf Therapeutics, an immuno-oncology specialist.
News and insights: regular updates on its investments and market commentary.

Who it works with

Its portfolio consists of high-growth companies, held both directly and through the funds it backs. The site reports the size of that underlying portfolio and its total commitments as at March 2022.

Key facts

Based in: Sheffield, UK
Type: investor in growth companies and venture funds

Summary written by TrustList from the business's own published information, Oct 2026.

Gallery

2 images - click to enlarge

Categories & features

Rankings

British Patient Capital is ranked on 3 TrustList rankings: #3 on 1, #26 on 1 and #38 on 1.

Every ranking orders its listings by their reviews, how complete the profile is and the Trust Score. British Patient Capital has no reviews yet and 3 of the 10 profile details we look for. Where no listing on a page has been reviewed, the order follows the profiles alone.

Investor · 3 rankings

#3of 9
United kingdom
It is the only one of the 9 here listing biotech and one of 2 here listing growth stage.
Of the 9 here, 5 also cover angel network and 4 also cover seed stage; 4 also work in London.
Behind Oceanwood Capital Management, ahead of Angel Investment Network.
#26of 52
Biotech investors
It is one of 10 here listing growth stage.
Of the 52 here, 14 also cover healthtech and 11 also cover science; 15 also work in Boston and 12 also work in New York City.
Behind Breyer Capital, ahead of Cambridge Innovation Capital.
#38of 100
Growth stage
It is one of 8 here listing biotech.
Of the top 64 here, 14 also cover series a and 12 also cover SaaS; 16 also work in San Francisco and 8 also work in Silicon Valley.
Behind BootstrapLabs, ahead of Canvas Ventures.